ssmuБюллетень сибирской медициныBulletin of Siberian Medicine1682-03631819-3684Siberian State Medical University, the Ministry of Healthcare of the Russian Federation10.20538/1682-0363-2004-3-31-35ssmu-3645Research ArticleРЕЗУЛЬТАТЫ ИССЛЕДОВАНИЙ МОЛОДЫХ УЧЕНЫХ И СТУДЕНТОВTHE RESULTS OF YOUNG SCIENTISTS’ AND STUDENTS’ INVESTIGATIONSЭпидемиологическое исследование эффективности превентивной фармакотерапии бронхиальной астмы (ETAC)Epidemiologic investigation of the efficiency of bronchial asthma preventive pharmacotherapy (ETAC)ФедороваО. С.FyodorovaO. S.

г. Томск

ПетровскаяЮ. А.PetrovskayaYu. A.

г. Томск

ФедотоваМ. М.FedotovaM. M.

г. Томск

Сибирский государственный медицинский университетRussian Federation200430092004333135Copyright © Федорова О.С., Петровская Ю.А., Федотова М.М., 20042004Федорова О.С., Петровская Ю.А., Федотова М.М.Fyodorova O.S., Petrovskaya Y.A., Fedotova M.M.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://bulletin.ssmu.ru/jour/article/view/3645

В последнее десятилетие в ряде стран проведены многочисленные исследования по изучению эффективности различных направлений первичной профилактики бронхиальной астмы (БА). В настоящей статье дан обзор публикаций, посвященных анализу результатов крупнейшего популяционного исследования ETAC (Early Treatment of the Atopic Child).

During the last decade numerous investigations on the study of different guidelines efficiency in primary prophylaxis of bronchial asthma (BA) has been fulfilled. In the present article a publication review devoted to the analysis of the greatest population investigation (ETAC – Early Treatment of the Atopic Child) results has been presented.

бронхиальная астмаатопияпревентивная фармакотерапияцетиризинbronchial asthmaatopypreventive pharmacotherapycetirizineReferencesОгородова Л.М., Астафьева Н.Г. Факторы риска астмы // Консилиум-медикум. 2001. Приложение. С. 4—8.Огородова Л.М., Астафьева Н.Г. Факторы риска астмы // Консилиум-медикум. 2001. Приложение. С. 4—8.Огородова Л.М., Федорова О.С., Петровская Ю.А., Петровский Ф.И. Эффективность первичной профилактики бронхиальной астмы // Рос. вест. перинатологии и педиатрии. 2003. ‹ 6. С. 27—30.Огородова Л.М., Федорова О.С., Петровская Ю.А., Петровский Ф.И. Эффективность первичной профилактики бронхиальной астмы // Рос. вест. перинатологии и педиатрии. 2003. ‹ 6. С. 27—30.Смоленов И.В., Машукова Н.Г. Первичная профилактика бронхиальной астмы у детей // Консилиум-медикум. 2001. Приложение. С. 17—21.Смоленов И.В., Машукова Н.Г. Первичная профилактика бронхиальной астмы у детей // Консилиум-медикум. 2001. Приложение. С. 17—21.Bachert C. Minimal persistent inflammation and its clinical consequences // The UCB Institute of Allergy. 2001.Bachert C. Minimal persistent inflammation and its clinical consequences // The UCB Institute of Allergy. 2001.Becker A.B., Chan-Yeung M. Primary prevention of asthma // Current Opin. Pulm. Med. 2002. ‹ 8 (1). P. 16—24.Becker A.B., Chan-Yeung M. Primary prevention of asthma // Current Opin. Pulm. Med. 2002. ‹ 8 (1). P. 16—24.Bustos G.J., Bustos D., Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study // Clin. Exp. Allergy. 1995. ‹ 25(6). P. 568—573.Bustos G.J., Bustos D., Romero O. Prevention of asthma with ketotifen in preasthmatic children: a three-year follow-up study // Clin. Exp. Allergy. 1995. ‹ 25(6). P. 568—573.De Longueville M. What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? // Pediatric Allergy and Immunology. 2000. V. 11. ‹ 13. P. 41—44.De Longueville M. What are the candidate groups for pharmacotherapeutic intervention to prevent asthma? // Pediatric Allergy and Immunology. 2000. V. 11. ‹ 13. P. 41—44.Diepgen T.L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, placebo-controlled trial (the ETAC trial) over 18 months // Pediatric Allergy and Immunology. 2002. ‹ 13(4). P. 278—86.Diepgen T.L. Long-term treatment with cetirizine of infants with atopic dermatitis: a multi-country, double-blind, placebo-controlled trial (the ETAC trial) over 18 months // Pediatric Allergy and Immunology. 2002. ‹ 13(4). P. 278—86.ETAC. Early Treatment of the Atopic Child. First result. The UCB Institute of Allergy. 2001.ETAC. Early Treatment of the Atopic Child. First result. The UCB Institute of Allergy. 2001.ETAC study group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC // Pediatric Allergy and Immunology. 1998. ‹ 9. Р. 116—124.ETAC study group. Allergic factors associated with the development of asthma and the influence of cetirizine in a double-blind, randomised, placebo-controlled trial: First results of ETAC // Pediatric Allergy and Immunology. 1998. ‹ 9. Р. 116—124.Gern J.E., Lemanske R.F. Pediatric allergy: can it be prevented? // Pediatric Allergy and Immunology. 1999. V. 19. ‹ 2. P. 233—252.Gern J.E., Lemanske R.F. Pediatric allergy: can it be prevented? // Pediatric Allergy and Immunology. 1999. V. 19. ‹ 2. P. 233—252.Global Initiative For Asthma. National Institute of Lung, Heart and Blood. 2002.Global Initiative For Asthma. National Institute of Lung, Heart and Blood. 2002.Gore C., Custovic A. Preventive measures and their effects. Results from cohort studies // Paediatric Respiratory Reviews. 2002. V. 3. ‹ 3. P. 205—218.Gore C., Custovic A. Preventive measures and their effects. Results from cohort studies // Paediatric Respiratory Reviews. 2002. V. 3. ‹ 3. P. 205—218.Host A., Halken S. Can we apply clinical studies to real life? Evidence-based recommendations from studies on development of allergic diseases and allergy prevention // Allergy. 2002. V. 57. ‹ 5. P. 389—399.Host A., Halken S. Can we apply clinical studies to real life? Evidence-based recommendations from studies on development of allergic diseases and allergy prevention // Allergy. 2002. V. 57. ‹ 5. P. 389—399.Likura Y., Naspitz C.K., Mikawa H. et al. Prevention of asthma by ketotifen in infants with atopic dermatitis // Ann. Allergy. 1992. ‹ 68(3). P. 233—236.Likura Y., Naspitz C.K., Mikawa H. et al. Prevention of asthma by ketotifen in infants with atopic dermatitis // Ann. Allergy. 1992. ‹ 68(3). P. 233—236.Martinez F. Is prevention of asthma possible? // Parallel session «Asthma and allergy — early markers and predictors». Pediatric Respiratory and Allergy Congress. April 1—4, 2001.Martinez F. Is prevention of asthma possible? // Parallel session «Asthma and allergy — early markers and predictors». Pediatric Respiratory and Allergy Congress. April 1—4, 2001.Prevention of Allergy and Asthma. Interim report. ACI International. 12/6 2001.Prevention of Allergy and Asthma. Interim report. ACI International. 12/6 2001.Ridoux S.M., Tariq S.M. Cetirizine overdose in a young child // J. of Allergy and Clin. Immunology. 1997. ‹ 99. P. 860—861.Ridoux S.M., Tariq S.M. Cetirizine overdose in a young child // J. of Allergy and Clin. Immunology. 1997. ‹ 99. P. 860—861.Silverman M. Markers of asthma // Parallel session «Asthma and allergy — early markers and predictors». Pediatric Respiratory and Allergy Congress. April 1—4, 2001.Silverman M. Markers of asthma // Parallel session «Asthma and allergy — early markers and predictors». Pediatric Respiratory and Allergy Congress. April 1—4, 2001.Stanciu L.A., Djucanovic R. The role of ICAM-1 on T-cells in the pathogenesis of asthma // Europ. Respir. J. 1998. ‹ 11. P. 949—957.Stanciu L.A., Djucanovic R. The role of ICAM-1 on T-cells in the pathogenesis of asthma // Europ. Respir. J. 1998. ‹ 11. P. 949—957.Stevenson J., Cornah D., Evrard P. et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis // Pediatric Respiratory. 2002. ‹ 52(2). P. 251—257.Stevenson J., Cornah D., Evrard P. et al. Long-term evaluation of the impact of the H1-receptor antagonist cetirizine on the behavioral, cognitive and psychomotor development of very young children with atopic dermatitis // Pediatric Respiratory. 2002. ‹ 52(2). P. 251—257.Wanh U., Mutius E. Childhood risk factors for atopy and the importance of early intervention // J. of Allergy and Clin. Immunology. 2001. ‹ 107. P. 567—574.Wanh U., Mutius E. Childhood risk factors for atopy and the importance of early intervention // J. of Allergy and Clin. Immunology. 2001. ‹ 107. P. 567—574.Wanh U. What drives the allergic march? // Allergy. 2000. ‹ 55. P. 591—599.Wanh U. What drives the allergic march? // Allergy. 2000. ‹ 55. P. 591—599.Warner J.O. and the ETAC study group. A double-blind, randomised, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis:18 months’ treatment and18 months’ post treatment follow-up // J. of Allergy and Clin. Immunology. 2001 (submitted).Warner J.O. and the ETAC study group. A double-blind, randomised, placebo-controlled trial of cetirizine in preventing the onset of asthma in children with atopic dermatitis:18 months’ treatment and18 months’ post treatment follow-up // J. of Allergy and Clin. Immunology. 2001 (submitted).Warner J.O. The ETAC study’s results // The UCB Institute of Allergy. 2001.Warner J.O. The ETAC study’s results // The UCB Institute of Allergy. 2001.Wolkerstorfer A., Wahn U., Kjellman N.I. et al. Natural course of sensitization to cow’s milk and hen’s egg in childhood atopic dermatitis: ETAC study group // Clin. Exp. Allergy. 2002. ‹ 32(1). Р. 70—3.Wolkerstorfer A., Wahn U., Kjellman N.I. et al. Natural course of sensitization to cow’s milk and hen’s egg in childhood atopic dermatitis: ETAC study group // Clin. Exp. Allergy. 2002. ‹ 32(1). Р. 70—3.Wright A.L. Analysis of epidemiological studies: facts and artifacts // Paediatric Respiratory Reviews. 2002. V. 3. ‹ 3. P. 198—204.Wright A.L. Analysis of epidemiological studies: facts and artifacts // Paediatric Respiratory Reviews. 2002. V. 3. ‹ 3. P. 198—204.

The authors declare that there are no conflicts of interest present.